SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • October 9th, 2009 • Oxis International Inc • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of October 1, 2009, between OXIS International, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
0% CONVERTIBLE DEBENTURE DUE OCTOBER 1, 2011Oxis International Inc • October 9th, 2009 • Pharmaceutical preparations • New York
THIS 0% CONVERTIBLE DEBENTURE is one of a series of duly authorized and validly issued 0% Convertible Debentures of OXIS International, Inc., a Delaware corporation, (the “Company”), having its principal place of business at _____________________________, designated as its 0% Convertible Debenture due October 1, 2011 (this debenture, the “Debenture” and, collectively with the other debentures of such series, the “Debentures”).
Series B COMMON STOCK PURCHASE WARRANT OXIS INTERNATIONAL, INC.Oxis International Inc • October 9th, 2009 • Pharmaceutical preparations
THIS Series B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from OXIS International, Inc., a Delaware corporation (the “Company”), up to ______ shares (the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
STANDSTILL AND FORBEARANCE AGREEMENTStandstill and Forbearance Agreement • October 9th, 2009 • Oxis International Inc • Pharmaceutical preparations • New York
This Standstill and Forbearance Agreement (this “Agreement”) is made and entered into as of October 1, 2009 by and among OXIS International, Inc., a Delaware corporation (“OXIS” or the “Company”) and Bristol Investment Fund, Ltd. (the “Lender”).
OXIS LETTERHEAD]Oxis International Inc • October 9th, 2009 • Pharmaceutical preparations
This letter is to inform you that Oxis International, Inc., a Delaware Corporation (the "Company") is contemplating entering into an agreement to pursue additional financing. The financing consists of the issuance of up to $2,000,000 worth of 0% Convertible Debentures and Warrants to accredited investors which shall close on or prior to October 1, 2009 (the “Additional Financing”).
